Geode Capital Management, LLC Gain Therapeutics, Inc. Transaction History
Geode Capital Management, LLC
- $1.21 Trillion
- Q3 2024
A detailed history of Geode Capital Management, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 271,972 shares of GANX stock, worth $424,276. This represents 0.0% of its overall portfolio holdings.
Number of Shares
271,972
Previous 183,736
48.02%
Holding current value
$424,276
Previous $235,000
105.96%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$917,9190.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$883,1620.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$521,9630.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$226,5380.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$191,8800.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...